Acute congestion is common in patients with heart failure (HF) and is associated with impaired renal function, reduced quality of life, hospital readmissions, and mortality. Current guidelines recommend optimal decongestion using diuretic therapy, mainly loop diuretics. Although acetazolamide has recently demonstrated efficacy in hospitalized patients, its role in ambulatory patients managed through remote telemonitoring remains to be established. This study aims to evaluate the efficacy of oral acetazolamide added to conventional treatment for decongesting ambulatory HF patients during congestive decompensations.
ACHIEVE is a Phase III multicenter, prospective, interventional, randomized, controlled, open-label superiority trial evaluating the efficacy of oral acetazolamide added to conventional treatment for decongestion in ambulatory patients with heart failure during congestive decompensation monitored by remote telemonitoring.
The primary objective is to assess, at Day 5, whether acetazolamide added to conventional treatment improves decongestion compared with standard treatment alone. Secondary objectives include evaluating efficacy, safety, and health economic outcomes, including quality of life, dyspnea, biological markers, unplanned consultations, hospitalizations, mortality, and hospital medical costs.

开始日期2026-10-01

申办/合作机构

University Hospital of Montpellier

NCT07593612

/ Not yet recruiting临床4期

TACTIC-HF: Thiazide or Acetazolamide Combination Versus Intravenous Furosemide in Ambulatory Worsening Heart Failure - a Randomized Crossover Trial

TACTIC-HF is a prospective randomized crossover trial designed to compare three ambulatory diuretic strategies in patients with worsening heart failure treated in a specialized heart failure day-hospital program.
Participants will receive sequential treatment with:
1. intravenous furosemide alone,
2. intravenous furosemide combined with oral acetazolamide, and
3. intravenous furosemide combined with oral hydrochlorothiazide.
The primary objective is to compare short-term natriuretic response between strategies. Secondary objectives include assessment of urine output, congestion parameters, and renal/electrolyte safety.
Each participant will undergo repeated outpatient treatment sessions separated by washout periods, with standardized clinical and laboratory monitoring performed during each visit.
The study aims to evaluate pragmatic and clinically applicable ambulatory decongestion strategies using approved therapies commonly available in real-world practice.

开始日期2026-06-15

申办/合作机构

Instituto Cardiovascular De Buenos Aires SA

CTR20261197

/ Active, not recruitingN/A

乙酰唑胺片在中国健康试验参与者中进行的单中心、随机、开放、单次（空腹/餐后）口服给药、两制剂、两序列、两周期、交叉的人体生物等效性预试验

主要目的:观察中国健康试验参与者在空腹/餐后状态下单次口服受试制剂乙酰唑胺片(规格:0.25g;持证商和生产企业:石家庄格瑞药业有限公司)和参比制剂乙酰唑胺片(商品名:Diamox;规格:0.25g;持证商和生产企业:Sanwa Kagaku Kenkyusho Co.,Ltd.)后的药代动力学特征,初步评价空腹/餐后状态下两种制剂的生物等效性,为正式试验提供依据。次要目的:观察受试制剂乙酰唑胺片和参比制剂乙酰唑胺片(Diamox)在中国健康试验参与者中的安全性。

开始日期2026-04-13

申办/合作机构

石家庄格瑞药业有限公司

100 项与乙酰唑胺相关的临床结果

登录后查看更多信息

100 项与乙酰唑胺相关的转化医学

登录后查看更多信息

100 项与乙酰唑胺相关的专利（医药）

登录后查看更多信息

9,072

项与乙酰唑胺相关的文献（医药）

2026-12-01·AQUATIC TOXICOLOGY

Polyethylene terephthalate (PET) nanoplastics target carbonic anhydrase and alter physiological functions in Daphnia magna

Article

作者: Lionetto, Francesca ; Polo, Gregorio ; Lionetto, Maria Giulia ; Giordano, Maria Elena ; Vignes, Fabio ; Mele, Claudio

Polyethylene terephthalate (PET) nanoplastics are increasingly recognized as relevant contaminants in freshwater ecosystems, yet the molecular mechanisms underlying their sublethal biological effects remain poorly understood. The aim of this study was to investigate whether true-to-life polyethylene terephthalate (PET) nanoplastics, generated from post-consumer PET bottles, affect carbonic anhydrase (CA) activity in Daphnia magna and whether such molecular alteration is associated with physiological dysfunction at the organism level. Label-free PET nanoplastics were generated from post-consumer bottles through a solvent-free mechanical fragmentation process designed to mimic environmental degradation and were characterized by a bimodal size distribution, with peaks centered at 185 and 538 nm. Using a pharmacological loss-of-function approach with acetazolamide, we first demonstrated that CA contributes to hemolymph pH regulation, gastrointestinal acidification, feeding activity, heart rate, and appendage movement in D. magna. In vitro exposure of whole-body homogenates to PET nanoplastics (0.5-5 mg/L) caused a clear dose-dependent inhibition of CA esterase activity, reaching about 54% at 5 mg/L. Short-term in vivo exposure (24 h) confirmed significant CA inhibition, with reductions of up to about 33%, and was accompanied by parallel decreases in heart rate and thoracic appendage beating frequency. By integrating particle characterization with in vitro and in vivo evidence, this study provides mechanistic support for CA-mediated disruption as a relevant pathway of PET nanoplastic toxicity in freshwater zooplankton. Our findings highlight CA as a promising mechanistic biomarker for nanoplastic exposure and contribute to the ecotoxicological assessment of PET nanoplastics in freshwater environments.

2026-12-01·BRAIN & DEVELOPMENT

Pediatric pseudotumor cerebri syndrome: Clinical characteristics, management and outcomes in a single-center cohort

Article

作者: Prando, Michela ; Paini, Giulia ; Caiazza, Laura ; Esposito, Susanna ; De Luisa, Angelica ; Giacomelli, Giovanna ; Scullin, Silvia ; Piccolo, Benedetta ; Turco, Emanuela Claudia ; Pera, Maria Carmela ; Gnazzo, Martina

OBJECTIVE:

Pediatric pseudotumor cerebri syndrome (PTCS) differs from adult disease in epidemiology, risk factors and clinical presentation. Female predominance and obesity are typically reported after puberty, while secondary forms are more frequent in younger children. Due to limited data on prepubertal patients, this study aimed to analyze clinical features, management and outcomes of pediatric PTCS, focusing on metabolic factors and disease course.

METHODS:

We retrospectively analyzed 14 children and adolescents diagnosed with PTCS in a pediatric center between 2015 and 2025, according to Friedman criteria. Data included demographics, pubertal status, body mass index, presenting symptoms, secondary causes, treatments and outcomes over 12 months. Additional post-study follow-up was performed when available.

RESULTS:

Female predominance was observed regardless of pubertal status. All patients were overweight or obese at diagnosis. Headache was the most frequent presenting symptom (85.7%), often accompanied by visual symptoms. Papilledema was present in all patients. Secondary PTCS occurred in three patients. Treatment included weight loss and acetazolamide in all patients. At 12 months, complete clinical and ophthalmologic remission was achieved in 64.3%. Recurrences occurred in three patients, both early and late: two required surgical interventions.

CONCLUSION:

PTCS should be suspected in overweight or obese children and adolescents presenting with persistent headache or visual symptoms, regardless of pubertal status. Early diagnosis, weight control and regular ophthalmologic monitoring are essential to reduce the risk of permanent visual impairment. Long-term follow-up is necessary, as relapses may occur beyond the first year after diagnosis. Prospective studies are warranted to confirm these findings.

2026-12-01·SEIZURE-EUROPEAN JOURNAL OF EPILEPSY

Acetazolamide in drug-resistant epilepsy: a systematic review with meta-analysis

Article

作者: Mehta, Amar A ; Lasker, Bruce R ; Arasu, Shanjali Arulmozhi

BACKGROUND:

Drug-resistant epilepsy (DRE) remains a high-morbidity condition despite expanding antiseizure medications. Acetazolamide (ACZ), a carbonic anhydrase inhibitor introduced for epilepsy in the 1950s, has been largely displaced by newer agents and concerns about tolerance, but its low cost and pH-mediated mechanism support reassessment in select DRE contexts.

METHODS:

We conducted a PROSPERO-registered, PRISMA-S-informed systematic review of clinical studies evaluating ACZ as mono- or adjunctive therapy for drug-resistant or refractory epilepsy through May 11, 2026. Risk of bias was assessed using Newcastle-Ottawa and ROBINS-I frameworks. To quantify treatment efficacy random-effects generalized linear mixed-model meta-analyses estimated seizure freedom and ≥50% responder rate.

RESULTS:

Twenty-six studies were included. The pooled seizure-freedom proportion was 25.7% (95% CI, 15.8%-38.9%; k = 20; I² = 89.5%) and ≥50% responder proportion 67.5% (95% CI, 48.2%-82.2%; k = 26; I² = 96.7%). Leave-one-out analysis did not identify a single influential study nor did exploratory meta-regression show a significant age-response correlation. Phenotype-specific and narrative findings demonstrated more consistent response in certain catamenial, spike-wave, photosensitive, genetic, and metabolic epilepsy contexts. Metabolic acidosis, nephrolithiasis, and treatment discontinuation were comparatively uncommon, whereas adverse effects were predominantly tolerability-related.

CONCLUSION:

ACZ retains a measurable but selective antiseizure signal in DRE. However, limitations in decades-old reporting, considerable between-study heterogeneity, limited controlled clinical evidence, and modest sample sizes in phenotype-specific cohorts require researchers to interpret the evidence with caution. Nevertheless, ACZ's observed clinical activity, low cost, and distinct mechanism of action make it a promising candidate for prospective studies to identify responsive epilepsy types, assess the durability of benefit, and redefine its place in modern epilepsy care.

118

项与乙酰唑胺相关的新闻（医药）

2026-10-14

·药智新闻

多款重磅新药获批上市

导读：2026年3季度上市药品情况 2026年3季度，新增1119个上市批文，涉及853个品种（药品+企业）。获批的22个1类创新药中，包括10个化药、9个生物制品和3个中药，并附详细名单。 01 2026年上市药品概览据药智数据-中国上市药品数据库统计，至2026年9月30日，2026年国家药监局批准了2643个品种（药品+企业）上市，包括2526个化药、81个生物制品和36个中药，共3423个批文。 2026年3季度，新增1119个批文，共853个品种，包括823个化药、21个生物制品和9个中药品种。图1 2026年上市药品情况 2026年进口共有98个品种药品批准在国内销售，其中64个为原研药品。3季度进口的18个药品（含7个原研），仅占3季度总品种的2.11%。说明本土企业的药品研发水平也在快速增长，越来越多的创新药和仿制药企业将市场着眼于国内。 2026年上市的146个原研药品（未统计古代经典名方）中，国产原研有82个，占原研药品的56.16%。3季度共有28个原研药品上市，其中1类创新药22个，18个为国产药品。 PS：药智数据公众号后台回复【上市2026】，免费下载报告PDF版。 02 化药上市情况 2026年3季度共有823个化学药品上市，包括12个原研药品（含10个创新药）和811个化学仿制药。原研药品方面，12个原研药品中，国产原研有8个（含6个1类创新药和2个改良型新药）。国产1类创新药治疗领域分布于肿瘤、泌尿系统、抗免疫系统方面。在仿制药品方面，仍旧以4类药品申报上市品种数最多，占比为59.30%；其次是3类（共314个，占比为38.15%）；其中西藏奥斯必秀医药有限公司的聚乙二醇4000散的规格4g以3类申报，规格10g以4类申报，所以按注册分类的总品种数据比总的品种数多1个。以5.2类进口的仿制药共6个，包括部分品种为国内已有较多企业获批上市的仿制药，如他达拉非片、熊去氧胆酸片、泮托拉唑钠肠溶片等。综上所述，进口仿制药不再是仿制药申报的主流。图2 2026年3季度上市化学药品注册分类药品生产企业数方面，药品同质化严重，仅18个品种为独家生产。超20家企业生产的有379个品种，占3季度上市化药的46.05%，包括3个以5.2类进口的仿制药，仿制药市场情势严峻。在严峻的市场情势下，各企业顺应发展变化，着力提升研发实力。除了对新药的开发，部分企业着眼于国外已上市国内未上市药品，并取的一定成果。3季度，有4个独家生产的化学仿制药以3类获批，分别为：甜菜碱散、巴氯芬注射液、乙酰唑胺缓释胶囊和左甲状腺素钠口服溶液。 03 中药上市情况在中药方面，2026年共有36个中药品种获批，包括4个1类创新药、20个古代经典名方、3个同名同方和8个港澳外用中成药。 3季度获批的9个中药品种，包括3个1类创新药、3个3.1类古代经典名方、2个同名同方和1个进口中药。 04 生物制品上市情况 2026年共有81个生物制品上市，其中27个为1类创新药；3季度共有21个品种获批，1类创新药9个。 3季度获批上市的生物制品有21个，国产药品18个，10个为独家生产；进口药品3个，2个独家。独家生产的国产生物制品，证明了我国企业对生物制品的研发水平正在不断提升；并且单克隆抗体的研发国内已经进入成熟期。 PS：药智数据公众号后台回复【上市2026】，免费下载报告PDF版。精选推荐 2026全球新药研发合集 2026中国药物临床试验合集 2026CDE药审月报合集 2026一致性评价月报合集 2026医药交易分析合集药品品类零售市场销售分析报告合集药品品种零售市场销售分析报告合集药品零售市场洞察及消费者研究报告合集 2025年度实体药店销售市场分析报告 2025年度药品全终端销售市场分析报告 2025年度药品医院市场销售分析报告 2025年度药品电商市场销售分析报告声明：本文仅作信息传递之目的，并不代表本平台观点。本文也不是治疗方案推荐，如需获得治疗方案指导，请前往正规医院就诊。如涉及作品内容、版权和其它问题，请在本平台留言，我们将在第一时间核实并处理。责任编辑 | 小二排版设计 | 小白合作、投稿、转载开白 | 陈老师 17308362010（同微信）

2026-10-12

·信狐药迅

百时美施贵宝Iberdomide胶囊进口获批；第一三共德曲妥珠单抗、德达博妥单抗进口获批|新获批（10.05-10.11）

每周药品注册获批数据，分门别类呈现，一目了然。(10.05-10.11）新药上市申请药品名称企业注册分类受理号新药临床申请药品名称企业注册分类受理号 ICP-B161注射液北京诺诚健华医药科技有限公司 1 CXSL2600954 BNT3219注射液百欧恩泰(珠海)医药研发有限公司 1 CXSL2600958 注射用GB268 亿腾医药(珠海)有限公司 1 CXSL2600949 阿得贝利单抗注射液上海盛迪医药有限公司 2.2 CXSL2600811 ABBV-701注射液艾伯维医药贸易(上海)有限公司 1 CXSL2600809 注射用DR30206 浙江道尔生物科技有限公司 1 CXSL2600800 注射用AMT-676 普众发现医药科技(上海)股份有限公司 1 CXSL2600801 注射用 AST-006 深圳艾欣达伟医药科技有限公司 1 CXHL2600943 F1F3软膏中奥生物医药技术(广东)有限公司 1 CXHL2600941 F1F3软膏中奥生物医药技术(广东)有限公司 1 CXHL2600940 SCT810注射液神州细胞工程有限公司 1 CXSL2600805 ARTS-980片安锐生物医药科技(广州)有限公司 1 CXHL2600951 ARTS-980片安锐生物医药科技(广州)有限公司 1 CXHL2600950 HRS-8046片成都盛迪医药有限公司 1 CXHL2600945 HRS-8046片成都盛迪医药有限公司 1 CXHL2600944 注射用重组A型肉毒毒素(Sf9细胞,150 kD天然氨基酸序列) 苏州若弋生物科技有限公司 2.4 CXSL2600807 SL-0010 上海则正医药科技股份有限公司 2.4 CXHL2600949 SL-0010 上海则正医药科技股份有限公司 2.4 CXHL2600947 SL-0010 上海则正医药科技股份有限公司 2.4 CXHL2600946 QLS2406-1注射液上海齐鲁制药研究中心有限公司 1 CXSL2600797 注射用重组A型肉毒毒素(Sf9细胞,150 kD天然氨基酸序列) 苏州若弋生物科技有限公司 2.4 CXSL2600795 注射用重组A型肉毒毒素(Sf9细胞,150 kD天然氨基酸序列) 苏州若弋生物科技有限公司 2.4 CXSL2600794 CS43158片深圳微芯生物科技股份有限公司 1 CXHL2600938 CS43158片深圳微芯生物科技股份有限公司 1 CXHL2600937 SHR-2173注射液广东恒瑞医药有限公司 1 CXSL2600799 BGM0504片博瑞制药(苏州)有限公司 1 CXHL2600931 BGM0504片博瑞制药(苏州)有限公司 1 CXHL2600930 BGM0504片博瑞制药(苏州)有限公司 1 CXHL2600929 依沃西单抗注射液康方赛诺医药有限公司 2.2 CXSL2600786 JMN-2205片浙江杭煜制药有限公司 1 CXHL2600928 JMN-2205片浙江杭煜制药有限公司 1 CXHL2600927 JMN-2205片浙江杭煜制药有限公司 1 CXHL2600926 人脐带间充质干细胞Ⅱ型注射液浙江我武干细胞科技有限公司 1 CXSL2600780 Cizutamig注射液(皮下注射) 上海坦蒂生物医药科技有限公司 1 CXSL2600778 重组带状疱疹疫苗(CHO细胞) 国药中生生物技术研究院有限公司 1.3 CXSL2600771 LS205口崩片北京隆熙生物科技有限公司 2.2;2.4 CXHL2600903 重组呼吸道合胞病毒疫苗(CHO细胞) 北京绿竹生物技术股份有限公司 1.4 CXSL2600755 BCP601胰岛细胞注射液贝康医学科技有限公司 1 CXSL2600757 SYS6055注射液北京抗创联生物制药技术研究有限公司 1 CXSL2600762 冻干重组呼吸道合胞病毒疫苗(CHO细胞) 厦门万泰沧海生物技术有限公司 1.2 CXSL2600748 人脐带间充质干细胞注射液深圳市茵冠生物科技有限公司 1 CXSL2600740仿制药申请药品名称企业注册分类受理号贝派度酸依折麦布片山东朗诺制药有限公司 3 CYHL2600084 氨溴特罗口服溶液贵州黔药集团制药有限公司 3 CYHS2601590 苹果酸奈诺沙星氯化钠注射液江西远超医药科技有限公司 4 CYHS2600648 氧(气态) 安康市利平制氧有限公司 4 CYHS2504076 氧(液态) 伊犁鸿瑞坤源气体有限公司 4 CYHS2504034 磷酸奥司他韦颗粒海南海神同洲制药有限公司 3 CYHS2503975 注射用氢化可的松琥珀酸钠海南倍特药业有限公司 3 CYHS2503930 注射用氢化可的松琥珀酸钠海南倍特药业有限公司 3 CYHS2503929 磷苯妥英钠注射液成都倍特药业股份有限公司 3 CYHS2503928 磷苯妥英钠注射液成都倍特药业股份有限公司 3 CYHS2503927 聚乙二醇4000散西安安健药业有限公司 3 CYHS2502988 流感病毒裂解疫苗江苏金迪克生物技术股份有限公司 3.3 CXSS2500075 吸入用盐酸氨溴索溶液北京韩美药品有限公司 3 CYHS2502485 吸入用盐酸氨溴索溶液北京韩美药品有限公司 3 CYHS2502484 蔗糖羟基氧化铁咀嚼片四川国为制药有限公司 4 CYHS2502348 沙库巴曲缬沙坦钠片温州海鹤药业有限公司 4 CYHS2502355 沙库巴曲缬沙坦钠片温州海鹤药业有限公司 4 CYHS2502354 艾拉莫德片河北龙海药业股份有限公司 4 CYHS2502223 德谷门冬双胰岛素注射液宜昌东阳光长江药业股份有限公司 3.3 CXSS2500066 德谷门冬双胰岛素注射液宜昌东阳光长江药业股份有限公司 3.3 CXSS2500065 盐酸阿罗洛尔片湖南尚众合生物医药有限公司 4 CYHS2502127 双氯芬酸钠双释放肠溶胶囊上海惠永制药有限公司 4 CYHS2502074 乳果糖口服溶液大连百畅药物研发有限公司 4 CYHS2502116 乳果糖口服溶液大连百畅药物研发有限公司 4 CYHS2502114 乙酰半胱氨酸注射液山东如至生物医药科技有限公司 3 CYHS2502042 维生素K1注射液成都苑东生物制药股份有限公司 3 CYHS2502012 硫酸氨基葡萄糖胶囊山东百诺医药股份有限公司 4 CYHS2502010 洛索洛芬钠贴剂津药达仁堂集团股份有限公司新新制药厂 4 CYHS2501956 洛索洛芬钠贴剂津药达仁堂集团股份有限公司新新制药厂 4 CYHS2501955 利伐沙班颗粒广州大光制药有限公司 3 CYHS2501949 利伐沙班颗粒广州大光制药有限公司 3 CYHS2501948 布瑞哌唑片杭州和康药业有限公司 4 CYHS2501924 布瑞哌唑片杭州和康药业有限公司 4 CYHS2501923 布瑞哌唑片杭州和康药业有限公司 4 CYHS2501922 盐酸维拉帕米注射液安徽美来药业股份有限公司 3 CYHS2501844 盐酸考来维仑片浙江京新药业股份有限公司 3 CYHS2501828 硫酸氨基葡萄糖胶囊山东司邦得制药有限公司 4 CYHS2501836 维生素B12注射液海南慧通生物医药科技有限公司 3 CYHS2501770 盐酸奥洛他定片郑州韩都药业集团有限公司 4 CYHS2501737 硫酸氨基葡萄糖胶囊蒙肽制药有限公司 4 CYHS2501640 沙库巴曲缬沙坦钠片山东新华制药股份有限公司 4 CYHS2501636 厄贝沙坦氢氯噻嗪片广州白云山天心制药股份有限公司 4 CYHS2501627 盐酸乙哌立松片湖南九典制药股份有限公司 4 CYHS2501607 阿哌沙班片广东彼迪药业有限公司 4 CYHS2501594 利格列汀二甲双胍片(II) 宁波科尔康美诺华药业有限公司 4 CYHS2501578 利格列汀二甲双胍片(I) 宁波科尔康美诺华药业有限公司 4 CYHS2501577 注射用厄他培南江苏瑜兴医药科技有限公司 4 CYHS2501545 盐酸乙哌立松片上海博悦生物科技有限公司 4 CYHS2501543 苯磺酸左氨氯地平片湖南银泽华浩生物科技有限公司 4 CYHS2501542 苯磺酸左氨氯地平片湖南银泽华浩生物科技有限公司 4 CYHS2501541 特立氟胺片苏州长征-欣凯制药有限公司 4 CYHS2501483 硝普钠注射液广州泽盛药业科技有限公司 3 CYHS2501479 酒石酸美托洛尔片湖南春光九汇现代中药有限公司 4 CYHS2501371 酒石酸美托洛尔片湖南春光九汇现代中药有限公司 4 CYHS2501370 富马酸伏诺拉生片苏州中化药品工业有限公司 4 CYHS2501335 甘油磷酸钠注射液山东华鲁制药有限公司 4 CYHS2501295 甘油磷酸钠注射液山东华鲁制药有限公司 4 CYHS2501294 乙酰半胱氨酸注射液广东君康药业有限公司 3 CYHS2501276 艾拉莫德片山东现代医药科技有限公司 4 CYHS2501274 盐酸溴己新口服溶液湖北海美纳医药科技有限公司 3 CYHS2501253 甲磺酸溴隐亭片江苏诚康药业有限公司 4 CYHS2501222 盐酸托莫西汀口服溶液山东步长制药股份有限公司 4 CYHS2501212 骨化三醇注射液山西康成利安医药有限公司 4 CYHS2501193 布洛芬缓释胶囊郑州泰丰制药有限公司 4 CYHS2501183 双氯芬酸二乙胺乳胶剂海南紫程众投生物科技有限公司 4 CYHS2501153 双氯芬酸二乙胺乳胶剂海南紫程众投生物科技有限公司 4 CYHS2501152 乙酰唑胺片上海理想制药有限公司 3 CYHS2501142 吡美莫司乳膏江苏盈科生物制药有限公司 4 CYHS2501086 尼莫地平口服溶液石家庄四药有限公司 3 CYHS2501074 法莫替丁注射液安徽美来药业股份有限公司 3 CYHS2501060 法莫替丁注射液安徽美来药业股份有限公司 3 CYHS2501058 伊布替尼胶囊北京双鹭药业股份有限公司 4 CYHS2501011 盐酸丁螺环酮片河北龙海药业股份有限公司 3 CYHS2500983 酮洛芬凝胶苏州高迈药业有限公司 4 CYHS2500961 盐酸溴己新口服溶液北京双鹭药业股份有限公司 3 CYHS2500940 氟比洛芬凝胶贴膏浙江高跖医药科技股份有限公司 4 CYHS2500932 聚乙二醇3350散合肥盛秦医药科技有限公司 3 CYHS2500920 盐酸多西环素片德全药品(江苏)股份有限公司 3 CYHS2500910 盐酸舍曲林口服浓缩液海南海灵化学制药有限公司 3 CYHS2500823 利那洛肽胶囊江西科睿药业有限公司 4 CYHS2500805 吗啉硝唑氯化钠注射液西安京西双鹤药业有限公司 4 CYHS2500789 地夸磷索钠滴眼液山东华铂凯盛生物科技有限公司 4 CYHS2500796 琥珀酸曲格列汀片南京万融健诚医药科技有限公司 3 CYHS2500748 琥珀酸曲格列汀片南京万融健诚医药科技有限公司 3 CYHS2500747 硝酸甘油注射液广州合和医药有限公司 3 CYHS2500719 硝酸甘油注射液广州合和医药有限公司 3 CYHS2500718 精氨酸布洛芬颗粒湖北亨迪药业股份有限公司 4 CYHS2500727 精氨酸布洛芬颗粒湖北亨迪药业股份有限公司 4 CYHS2500726 注射用氟氧头孢钠海韬新药研发(江苏)有限公司 4 CYHS2500630 尿素[13C]呼气试验药盒深圳市中核海得威生物科技有限公司 3 CYHS2500629 奥美拉唑碳酸氢钠干混悬剂(I) 安徽四环科宝制药有限公司 3 CYHS2500492 奥美拉唑碳酸氢钠干混悬剂(Ⅱ) 安徽四环科宝制药有限公司 3 CYHS2500491 钆特酸葡胺注射液通用电气药业(上海)有限公司 4 CYHS2500456 钆特酸葡胺注射液通用电气药业(上海)有限公司 4 CYHS2500455 钆特酸葡胺注射液通用电气药业(上海)有限公司 4 CYHS2500454 硫酸镁钠钾口服用浓溶液海南斯达制药有限公司 4 CYHS2500252 磷酸奥司他韦颗粒中山万汉制药有限公司 3 CYHS2500204 注射用吲哚菁绿天津天士力之骄药业有限公司 3 CYHS2500039 氢溴酸加兰他敏口腔崩解片北京星昊医药股份有限公司 3 CYHS2404649 氢溴酸加兰他敏口腔崩解片北京星昊医药股份有限公司 3 CYHS2404648 草酸艾司西酞普兰口服溶液海南斯达制药有限公司 3 CYHS2404639 琥珀酸亚铁片河北龙海药业股份有限公司 3 CYHS2404621 艾曲泊帕乙醇胺干混悬剂广州市联瑞制药有限公司 3 CYHS2404528 铝碳酸镁混悬液湖南普道医药技术有限公司 3 CYHS2404466 重酒石酸去甲肾上腺素注射液山西普恒制药有限公司 3 CYHS2404450 头孢克肟颗粒广东华南药业集团有限公司 3 CYHS2404410 注射用吲哚菁绿江苏九旭药业有限公司 3 CYHS2404217 复方维生素C聚乙二醇(3350)钠钾散湖北莱康医疗技术有限公司 3 CYHS2403878 蛋白琥珀酸铁口服溶液湖北午时医药研究院有限公司 4 CYHS2403226 盐酸纳呋拉啡口腔崩解片湖北民康制药有限公司 4 CYHS2401881 培哚普利氨氯地平片(III) 上海安必生制药技术有限公司 4 CYHS2401205 甲磺酸沙非胺精华制药集团南通有限公司 CXHS2060040进口申请药品名称企业注册分类受理号 Giredestrant胶囊 F. Hoffmann-La Roche Ltd 1 JXHL2600397 Telisotuzumab Adizutecan 注射用粉末 AbbVie Inc. 1 JXSL2600181 Telisotuzumab Adizutecan 注射用粉末 AbbVie Inc. 1 JXSL2600180 Risankizumab注射液 AbbVie Inc. 2.2 JXSL2600185 Risankizumab注射液 AbbVie Inc. 2.2 JXSL2600184 ABBV-382注射液 AbbVie Inc. 1 JXSL2600183 DDY391片 Novartis Pharma AG 1 JXHL2600305 DDY391片 Novartis Pharma AG 1 JXHL2600304 乌帕替尼缓释片 AbbVie Inc. 2.4 JXHL2600308 ABBV-722薄膜衣片 AbbVie Inc. 1 JXHL2600307 ABBV-722薄膜衣片 AbbVie Inc. 1 JXHL2600306 AZD5335 AstraZeneca AB 1 JXSL2600179 注射用TAK-121 Takeda Development Center Americas, Inc. 1 JXHL2600303 注射用TAK-121 Takeda Development Center Americas, Inc. 1 JXHL2600302 注射用TAK-121 Takeda Development Center Americas, Inc. 1 JXHL2600301 注射用TAK-121 Takeda Development Center Americas, Inc. 1 JXHL2600300 注射用TAK-121 Takeda Development Center Americas, Inc. 1 JXHL2600299 Izicopan软胶囊 InflaRx GmbH 1 JXHL2600294 AZD4144薄膜包衣片 AstraZeneca AB 1 JXHL2600296 AZD4144薄膜包衣片 AstraZeneca AB 1 JXHL2600295 注射用德曲妥珠单抗 Daiichi Sankyo Europe GmbH 2.2 JXSS2600024 Iberdomide胶囊 Bristol-Myers Squibb Pharma EEIG 1 JXHS2500139 Iberdomide胶囊 Bristol-Myers Squibb Pharma EEIG 1 JXHS2500138 注射用德达博妥单抗 Daiichi Sankyo Europe GmbH 2.2 JXSS2500151 紫杉醇口服溶液 DAEHWA PHARMACEUTICAL CO.,LTD. 2.4 JXHS2500073 紫杉醇口服溶液 DAEHWA PHARMACEUTICAL CO.,LTD. 2.4 JXHS2500072 紫杉醇口服溶液 DAEHWA PHARMACEUTICAL CO.,LTD. 2.4 JXHS2500071 亮丙瑞林注射乳剂 Accord BioPharma Inc. 5.1 JXHS2500024中药相关申请药品名称企业注册分类受理号 1301-07颗粒中国药科大学 1.1 CXZL2600069 藿连消滞颗粒和光中药科技(天津)有限公司 1.1 CXZL2600067 复方野菊花颗粒浙江中医药大学 1.1 CXZL2600068 TDX105颗粒天士力医药集团股份有限公司 1.1 CXZL2600066 舒筋健腰丸广州白云山陈李济药厂有限公司 2.3 CXZL2600063 CHA756丸诺贝生物医药科技(山东)有限公司 1.1 CXZL2600065 季德胜蛇药片精华制药集团股份有限公司 2.3 CXZL2600062 注：绿色字体部分为潜在首仿品种；橙色字体部分结论为不批准或收到通知件；不包含原料药、医用氧、注射用水、氯化钠或葡萄糖注射液等申请，不包含再注册、一次性进口、技术转移、复审申请。

申请上市上市批准

2026-10-12

·BioSpace

Iridex Announces the Publication of Two-Year Independent Study Supporting Benefits of MicroPulse® Technology for Early to Advanced Glaucoma

Study reports sustained IOP reduction and reduced medication burden over 24 months SAN JOSE, Calif., Oct. 12, 2026 (GLOBE NEWSWIRE) -- Iridex Corporation (Nasdaq: IRIX), a worldwide leader in innovative laser-based medical systems, delivery devices, and accessories for the treatment of glaucoma and retinal diseases, today announced the publication of a two-year clinical study demonstrating favorable outcomes with transscleral laser therapy (TLT) using MicroPulse ® Technology (referred to as MicroPulse TLT) in patients with early, moderate, and advanced primary glaucoma. “These two-year results are particularly meaningful because they show sustained IOP reduction and reduced medication burden in patients with early-stage glaucoma, as well as in those with moderate and advanced disease,” said Michele Lanza, MD, lead author of the study. “The findings suggest that MicroPulse TLT may have a role earlier in the glaucoma treatment continuum than has traditionally been considered.” Published in the International Journal of Ophthalmology , the retrospective study evaluated 84 eyes of 53 patients with primary open-angle glaucoma (POAG) or primary angle-closure glaucoma (PACG). Led by Dr. Lanza of the Università della Campania Luigi Vanvitelli in Naples, Italy, the study used the Iridex Cyclo G6 ® Laser with the original MicroPulse ® P3 Delivery Device. Patients with prior incisional glaucoma surgery were excluded, while those who had undergone selective laser trabeculoplasty (SLT) more than three years earlier remained eligible for inclusion. “We are encouraged by the sustained outcomes reported in this study and the growing body of clinical evidence supporting MicroPulse TLT,” said Patrick Mercer, President and Chief Executive Officer of Iridex. “These findings further reinforce our commitment to advancing laser-based treatment options for patients with glaucoma.” Key Findings at 24 Months Mean intraocular pressure (IOP) decreased significantly from 22.32 mmHg at baseline to 14.05 mmHg, with reductions sustained throughout the two-year follow-up Mean number of topical IOP-lowering medications decreased from 2.96 at baseline to 2.38 Treatment success rates were 86% in POAG eyes and 81% in PACG eyes No complications or reductions in visual acuity were reported during follow-up Additional findings included the discontinuation of oral acetazolamide among all patients receiving the medication before MicroPulse TLT, with none requiring reinitiation during the two-year follow-up period. Further, visual field measurements remained stable during follow-up in both the POAG and PACG groups. About the Study Lanza M, Fattore I, Ambrosio S, Abbate F, Boccia R, Serra L, Cangiano T, Simonelli F. Safety and efficacy of micropulse transscleral laser therapy for glaucoma: a two-year follow-up. International Journal of Ophthalmology. 2026;19(9):1731-1738. doi:10.18240/ijo.2026.09.08. About Iridex Corporation Iridex Corporation is a worldwide leader in developing, manufacturing, and marketing innovative and versatile laser-based medical systems, which include capital equipment and consumable probes for the ophthalmology market. The Company’s proprietary MicroPulse ® technology delivers the therapeutic benefits of laser treatment while minimizing tissue damage, offering a safe, effective, and proven treatment for targeted sight-threatening eye conditions. Iridex’s current product line is used for the treatment of glaucoma and diabetic macular edema (DME) and other retinal diseases. Iridex products are sold in the United States through a direct sales force and internationally primarily through a network of independent distributors into more than 100 countries. For additional information, visit . Investor Relations Contact Philip Taylor Gilmartin Group investors@iridex.com Media Contact Joan Stauffer jstauffer@iridex.com Iridex, the Iridex logo, MicroPulse, the MicroPulse logo, Cyclo G6, and MicroPulse P3 are registered trademarks of Iridex.

临床结果

100 项与乙酰唑胺相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
D00218	乙酰唑胺	S01EC01	DB00819

研发状态

批准上市

10 条最早获批的记录,

后查看更多信息

适应症	国家/地区	公司	日期
先兆子痫	日本	Sanwa Kagaku Kenkyusho Co., Ltd.	1994-06-02
睡眠呼吸暂停综合征	日本	Sanwa Kagaku Kenkyusho Co., Ltd.	1988-03-29
高眼压症	中国	天津力生制药股份有限公司	1983-01-01
呼吸性酸中毒	日本	Sanwa Kagaku Kenkyusho Co., Ltd.	1955-03-29
青光眼	日本	Sanwa Kagaku Kenkyusho Co., Ltd.	1955-03-29
梅尼埃病	日本	Sanwa Kagaku Kenkyusho Co., Ltd.	1955-03-29
经前综合征	日本	Sanwa Kagaku Kenkyusho Co., Ltd.	1955-03-29
内分泌与代谢疾病	美国	Teva Women's Health, Inc.	1954-06-25
急性闭角型青光眼	美国	Teva Branded Pharmaceutical Products R&D LLC	1953-07-27
高原反应	美国	Teva Branded Pharmaceutical Products R&D LLC	1953-07-27
水肿	美国	Teva Branded Pharmaceutical Products R&D LLC	1953-07-27
癫痫	美国	Teva Branded Pharmaceutical Products R&D LLC	1953-07-27
开角型青光眼	美国	Teva Branded Pharmaceutical Products R&D LLC	1953-07-27
继发性青光眼	美国	Teva Branded Pharmaceutical Products R&D LLC	1953-07-27

未上市

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
类风湿关节炎	临床前	中国	安徽医科大学	2025-05-12

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT04975269 (DRAIN, Pubmed \| Lancet Neurol)	临床2期	正常压力脑积水	50	Acetazolamide	遞憲築選鑰壓蓋襯衊鏇(窪齋網衊襯蓋夢糧淵構) = 齋壓淵鏇窪簾醖齋淵製鹹齋艱鹹願憲淵築網蓋 (範夢膚顧鹹襯構憲窪選 ) 更多	不佳	2026-06-01
				Placebo	遞憲築選鑰壓蓋襯衊鏇(窪齋網衊襯蓋夢糧淵構) = 鏇築窪繭鑰糧願艱鏇鑰鹹齋艱鹹願憲淵築網蓋 (範夢膚顧鹹襯構憲窪選 ) 更多
AUA2026	N/A	体重下降 \| 偏头痛	246	Topiramate	鏇繭築積衊觸願願獵憲(積壓憲繭鬱窪願鑰範膚) = 餘壓繭網鹹鬱製壓艱製獵蓋構壓鹽壓廠鹹選醖 (淵遞遞選積遞製選醖衊, 4.27 ~ 5.65)	积极	2026-05-15
				Zonisamide	鏇繭築積衊觸願願獵憲(積壓憲繭鬱窪願鑰範膚) = 構範衊淵壓淵鏇窪顧選獵蓋構壓鹽壓廠鹹選醖 (淵遞遞選積遞製選醖衊, 5.84 ~ 10.96)
NCT05589792 (Pubmed \| Thorax)	临床2期	睡眠呼吸暂停综合征	11	Acetazolamide 500 mg	襯鹽膚鬱遞淵製遞憲網(襯積蓋製壓淵襯顧鬱積) = 獵窪夢艱觸構艱壓夢艱壓衊願淵繭觸襯衊網顧 (構網觸鹽鹽鹹艱膚膚襯 ) 更多	积极	2026-03-04
				Placebo	襯鹽膚鬱遞淵製遞憲網(襯積蓋製壓淵襯顧鬱積) = 衊齋憲廠襯壓膚簾膚憲壓衊願淵繭觸襯衊網顧 (構網觸鹽鹽鹹艱膚膚襯 ) 更多
NCT03156231 (Pubmed \| J Clin Sleep Med)	临床2期	慢性阻塞性肺疾病	43	Acetazolamide 375 mg/day	顧壓積製鬱窪範築繭繭(糧獵鏇鏇願獵獵窪淵製) = 遞鏇襯遞淵醖壓齋獵範齋遞選製艱憲艱蓋壓衊 (窪繭鹹膚遞觸構選醖顧 ) 更多	积极	2025-12-01
				Placebo	廠積積顧鏇願觸窪範獵(淵製範壓遞遞鬱蓋廠淵) = 餘鑰觸製齋衊夢繭築廠觸鏇獵醖廠積膚鹹衊選 (窪繭夢構餘蓋鑰鹽範憲 ) 更多
NCT03540914 (Pubmed \| J Am Heart Assoc)	临床2期	心脏衰竭	171	Acetazolamide 375 mg/day	構憲積鹽鹽鬱醖醖壓衊(製襯網選鹹蓋憲壓憲憲) = 壓築窪糧壓壓壓範選蓋簾醖構窪願繭觸遞願壓 (觸繭鹽鏇憲醖獵襯廠顧 ) 更多	不佳	2025-09-02
				Placebo	構憲積鹽鹽鬱醖醖壓衊(製襯網選鹹蓋憲壓憲憲) = 願獵構製繭糧齋壓繭齋簾醖構窪願繭觸遞願壓 (觸繭鹽鏇憲醖獵襯廠顧 )
NCT05411991 (DECONGEST, CTgov)	临床4期	音量过载 \| 心脏衰竭 \| 药物不良反应	107	UNa measurement after intravenous loop diuretic bolus+Intravenous bumetanide TID+Intravenous canrenoate 200 mg OD+Intravenous acetazolamide 500 mg OD+chlorthalidone (Intervention Arm)	範壓襯選窪夢願淵膚夢 = 衊製願繭窪願襯淵網鬱築糧繭憲壓廠鹹鹽膚範 (廠範鬱願築夢醖窪衊壓, 窪膚製壓選淵淵鹹膚衊 ~ 遞鏇製觸衊艱積淵衊鹹) 更多	-	2025-08-08
				Usual AHF care (Control Arm)	範壓襯選窪夢願淵膚夢 = 簾積繭醖遞壓餘蓋構鹹築糧繭憲壓廠鹹鹽膚範 (廠範鬱願築夢醖窪衊壓, 膚廠齋齋憲網鏇醖簾鬱 ~ 膚範網壓鏇遞窪獵餘鹹) 更多
APAO2025	N/A	葡萄膜炎黄斑水肿	187	Acetazolamide	築艱範網淵廠糧築醖膚(範鑰衊願簾鬱製壓蓋齋) = 觸鏇繭糧餘膚糧獵構選醖廠齋選醖遞構積築遞 (製窪願獵網壓夢顧蓋窪, 32 ~ 79) 更多	积极	2025-04-03
NCT04679389 (CTgov)	临床2/3期	1A型先天性糖基化障碍 \| 共济失调	25	Acetazolamide (Acetazolamide)	顧顧壓襯獵網繭願構廠(繭鏇鹽憲獵憲艱選鑰製) = 網遞醖餘窪膚範選鹽繭製艱膚繭觸襯艱遞醖淵 (齋選齋憲餘選夢顧鹹餘, 3.20) 更多	-	2025-03-20
				Placebo (Placebo)	顧顧壓襯獵網繭願構廠(繭鏇鹽憲獵憲艱選鑰製) = 觸齋觸選糧範構鑰製網製艱膚繭觸襯艱遞醖淵 (齋選齋憲餘選夢顧鹹餘, 3.23) 更多
NCT04639193 (RESCUE-Combo, Pubmed \| Ann Am Thorac Soc)	临床2期	阻塞性睡眠呼吸暂停综合征	20	Acetazolamide+eszopiclone	鬱淵鑰築壓積夢願顧簾(齋壓廠鏇窪窪襯憲襯構) = 憲築鑰選網獵鹹鑰糧獵憲選選選獵築壓積蓋艱 (壓繭觸願願糧襯夢廠壓, -24.1 ~ -5.2)	积极	2024-11-08
NCT03505788 (ADVOR Trial \| Advor, CTgov)	临床4期	音量过载 \| 代谢性疾病 \| 急性失代偿性心力衰竭	519	placebo (Placebo)	襯糧襯膚觸顧繭糧繭積 = 鹹遞衊構鏇餘壓膚襯簾淵鑰觸蓋壓築窪製獵鬱 (窪廠願艱築觸積齋鹹廠, 構衊獵衊顧顧夢餘窪襯 ~ 鬱艱艱製壓簾餘積淵簾) 更多	-	2024-10-28
				Acetazolamide (Acetazolamide)	襯糧襯膚觸顧繭糧繭積 = 遞獵糧顧夢餘鏇構襯壓淵鑰觸蓋壓築窪製獵鬱 (窪廠願艱築觸積齋鹹廠, 構齋鏇構醖構鹹鑰廠鹹 ~ 壓淵繭鏇遞鹹構餘遞遞) 更多